Literature DB >> 9042932

HLA class II DR-DQ amino acids and insulin-dependent diabetes mellitus: application of the haplotype method.

A M Valdes1, S McWeeney, G Thomson.   

Abstract

Insulin-dependent diabetes mellitus (IDDM) HLA class II DRB1-DQA1-DQB1 data from four populations (Norwegian, Sardinian, Mexican American, and Taiwanese) have been analyzed to detect the amino acids involved in the disease process. The combination of sites DRB1#67 and 86; DQA1#47; and DQB1#9, 26, 57, and 70 predicts the IDDM component in these four populations, when the results and criteria of the haplotype method for amino acids, developed in the companion paper in this issue of the Journal, are used. The following sites, either individually, or in various combinations, previously have been suggested as IDDM components: DRB1#57, 70, 71, and 86; DQA1#52; and DQB1#13, 45, and 57 (DQB1#13 and 45 correlates 100% with DQB1#9 and 26). We propose that DQA1#47 is a better predictor of IDDM than is the previously suggested DQA1#52, and we add DRB1#67 and DQB1#70 to the HLA DR-DQ IDDM amino acids. We do not claim to have identified all HLA DR-DQ amino acids-or highly correlated sites-involved in IDDM. The frequencies and predisposing/protective effects of the haplotypes defined by these seven sites have been compared, and the effects on IDDM are consistent across the populations. The strongest susceptible effects came from haplotypes DRB1 *0301/DQA1 *0501/ DQB1*0201 and DRB1*0401-5-7-8/DQA1*0301/ DQB1*0302. The number of strong protective haplotypes observed was larger than the number of susceptible ones; some of the predisposing haplotypes were present in only one or two populations. Although the sites under consideration do not necessarily have a functional involvement in IDDM, they should be highly associated with such sites and should prove to be useful in risk assessment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9042932      PMCID: PMC1712519     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  39 in total

1.  Detecting disease-predisposing variants: the haplotype method.

Authors:  A M Valdes; G Thomson
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

Review 2.  The search for IDDM susceptibility genes: the next generation.

Authors:  D Owerbach; K H Gabbay
Journal:  Diabetes       Date:  1996-05       Impact factor: 9.461

3.  HLA-encoded susceptibility to insulin-dependent diabetes mellitus is determined by DR and DQ genes as well as their linkage disequilibria in a Chinese population.

Authors:  H S Huang; J T Peng; J Y She; L P Zhang; C C Chao; K H Liu; J X She
Journal:  Hum Immunol       Date:  1995-12       Impact factor: 2.850

4.  Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association.

Authors:  J Hammer; F Gallazzi; E Bono; R W Karr; J Guenot; P Valsasnini; Z A Nagy; F Sinigaglia
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

5.  HLA-DQ-restricted, islet-specific T-cell clones of a type I diabetic patient. T-cell receptor sequence similarities to insulitis-inducing T-cells of nonobese diabetic mice.

Authors:  I Durinovic-Bellò; A Steinle; A G Ziegler; D J Schendel
Journal:  Diabetes       Date:  1994-11       Impact factor: 9.461

6.  Polymorphic amino acid variations in HLA-DQ are associated with systematic physical property changes and occurrence of IDDM. Members of the Swedish Childhood Diabetes Study.

Authors:  C B Sanjeevi; T P Lybrand; C DeWeese; M Landin-Olsson; I Kockum; G Dahlquist; G Sundkvist; D Stenger; A Lernmark
Journal:  Diabetes       Date:  1995-01       Impact factor: 9.461

7.  Improved risk assessment for insulin-dependent diabetes mellitus by analysis of amino acids in HLA-DQ and DRB1 loci.

Authors:  M Zamani Ghabanbasani; M Spaepen; I Buyse; P Marynen; M Bex; R Bouillon; J J Cassiman
Journal:  Eur J Hum Genet       Date:  1994       Impact factor: 4.246

Review 8.  Genetic analysis of type 1 diabetes using whole genome approaches.

Authors:  J A Todd
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

9.  The distribution of DR4 haplotypes in Sardinia suggests a primary association of type I diabetes with DRB1 and DQB1 loci.

Authors:  F Cucca; R Lampis; F Frau; D Macis; E Angius; P Masile; M Chessa; P Frongia; M Silvetti; A Cao; S De Virgiliis; M Congia
Journal:  Hum Immunol       Date:  1995-08       Impact factor: 2.850

10.  HLA-DRB1*0401 is associated with susceptibility to insulin-dependent diabetes mellitus independently of the DQB1 locus.

Authors:  B D Tait; B P Drummond; M D Varney; L C Harrison
Journal:  Eur J Immunogenet       Date:  1995-08
View more
  15 in total

1.  HLA-DRB1 the notorious gene in the mosaic of autoimmunity.

Authors:  María-Teresa Arango; Carlo Perricone; Shaye Kivity; Enrica Cipriano; Fulvia Ceccarelli; Guido Valesini; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Detecting disease-predisposing variants: the haplotype method.

Authors:  A M Valdes; G Thomson
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

3.  Association of selective HLA class II susceptibility-conferring and protective haplotypes with type 2 diabetes in patients from Bahrain and Lebanon.

Authors:  Wassim Y Almawi; Saria F Wakim-Ghorayeb; Mona R Arekat; Pierre Najm; Sose H Keleshian; Nasreen Al-Sayed; Bruno Blanchon; Hanady R Samaha; Noha Irani-Hakime
Journal:  Clin Vaccine Immunol       Date:  2006-09-20

Review 4.  Celiac disease-associated autoimmune endocrinopathies.

Authors:  V Kumar; M Rajadhyaksha; J Wortsman
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

5.  MHC region and risk of systemic lupus erythematosus in African American women.

Authors:  Edward A Ruiz-Narvaez; Patricia A Fraser; Julie R Palmer; L Adrienne Cupples; David Reich; Ying A Wang; John D Rioux; Lynn Rosenberg
Journal:  Hum Genet       Date:  2011-06-22       Impact factor: 4.132

6.  Several loci in the HLA class III region are associated with T1D risk after adjusting for DRB1-DQB1.

Authors:  A M Valdes; G Thomson
Journal:  Diabetes Obes Metab       Date:  2009-02       Impact factor: 6.577

7.  Sequence feature variant type (SFVT) analysis of the HLA genetic association in juvenile idiopathic arthritis.

Authors:  Glenys Thomson; Nishanth Marthandan; Jill A Hollenbach; Steven J Mack; Henry A Erlich; Richard M Single; Matthew J Waller; Steven G E Marsh; Paula A Guidry; David R Karp; Richard H Scheuermann; Susan D Thompson; David N Glass; Wolfgang Helmberg
Journal:  Pac Symp Biocomput       Date:  2010

8.  Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis.

Authors:  David R Karp; Nishanth Marthandan; Steven G E Marsh; Chul Ahn; Frank C Arnett; David S Deluca; Alexander D Diehl; Raymond Dunivin; Karen Eilbeck; Michael Feolo; Paula A Guidry; Wolfgang Helmberg; Suzanna Lewis; Maureen D Mayes; Chris Mungall; Darren A Natale; Bjoern Peters; Effie Petersdorf; John D Reveille; Barry Smith; Glenys Thomson; Matthew J Waller; Richard H Scheuermann
Journal:  Hum Mol Genet       Date:  2009-11-18       Impact factor: 6.150

9.  Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis.

Authors:  Stacy J Caillier; Farren Briggs; Bruce A C Cree; Sergio E Baranzini; Marcelo Fernandez-Viña; Patricia P Ramsay; Omar Khan; Walter Royal; Stephen L Hauser; Lisa F Barcellos; Jorge R Oksenberg
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

10.  High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions.

Authors:  Lisa F Barcellos; Suzanne L May; Patricia P Ramsay; Hong L Quach; Julie A Lane; Joanne Nititham; Janelle A Noble; Kimberly E Taylor; Diana L Quach; Sharon A Chung; Jennifer A Kelly; Kathy L Moser; Timothy W Behrens; Michael F Seldin; Glenys Thomson; John B Harley; Patrick M Gaffney; Lindsey A Criswell
Journal:  PLoS Genet       Date:  2009-10-23       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.